Expert review of respiratory medicine最新文献_第2页

Impulse oscillometry indices are associated with functional impairment and progressive pulmonary fibrosis across interstitial lung diseases. 脉冲振荡指标与间质性肺疾病的功能损害和进行性肺纤维化相关。

IF 2.7

Expert review of respiratory medicine Pub Date : 2026-09-01 Epub Date: 2026-05-25 DOI: 10.1080/17476348.2026.2678615

Eyal Kleinhendler, Tomer Hasson, Doron Cohn-Schwartz, Ariel Melloul, Sharon Enghelberg, Inbal Friedman Regev, Nimrod Urtreger, Aviv Kupershmidet, Amir Bar-Shai, Boaz Tiran, Ophir Freund, Avraham Unterman

{"title":"Impulse oscillometry indices are associated with functional impairment and progressive pulmonary fibrosis across interstitial lung diseases.","authors":"Eyal Kleinhendler, Tomer Hasson, Doron Cohn-Schwartz, Ariel Melloul, Sharon Enghelberg, Inbal Friedman Regev, Nimrod Urtreger, Aviv Kupershmidet, Amir Bar-Shai, Boaz Tiran, Ophir Freund, Avraham Unterman","doi":"10.1080/17476348.2026.2678615","DOIUrl":"10.1080/17476348.2026.2678615","url":null,"abstract":"Background: Respiratory oscillometry provides effort-independent indices of airway heterogeneity (R5-20) and respiratory system stiffness (AX). Their clinical relevance in interstitial lung diseases (ILD) remains unclear and was the aim of our study.Research design and methods: A cross-sectional study including patients with ILD who underwent oscillometry, pulmonary function tests (PFTs), and six-minute walking distance (6MWD) at a single visit. R5-20 and AX were analyzed as continuous variables and as thresholds derived from receiver operating characteristic (ROC) analysis for progressive pulmonary fibrosis (PPF). Associations with clinical outcomes were assessed using multivariable regression models.Results: Ninety-four patients (median age 70y; 44% females) were included. Oscillometry parameters correlated with PFTs and 6MWD, and had a moderate discriminative ability for PPF (AUC 0.747-0.764). Abnormal oscillometry was identified in 46 patients (49%) and was not associated with any baseline characteristic or ILD subtype. However, it was linked to lower DLCO (48% vs. 54% predicted, p = 0.02) and reduced 6MWD (median [IQR] 413 [354-503] vs. 465 [425-533] meters, p = 0.024). R5-20 was higher in patients with air-trapping or mosaic attenuation in chest CT, although not in those with honeycombing or traction bronchiectasis.Conclusion: Oscillometric abnormalities are common in ILD and independently associated with disease severity.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1127-1136"},"PeriodicalIF":2.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147978160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Health disparities in cystic fibrosis in the context of the exposome: recent developments and future directions. 暴露背景下囊性纤维化的健康差异：最近的发展和未来方向。

IF 2.7

Expert review of respiratory medicine Pub Date : 2026-09-01 Epub Date: 2026-05-26 DOI: 10.1080/17476348.2026.2679780

Gabriela R Oates, Crystal Stephens, Michael S Schechter

引用次数: 0

Bovhyaluronidase azoximer for long-term pulmonary sequelae of COVID19: a multicenter, randomized, double-blind, placebo-controlled study. bovhyalonidase azoximer治疗covid - 19长期肺部后遗症：一项多中心、随机、双盲、安慰剂对照研究

IF 2.7

Expert review of respiratory medicine Pub Date : 2026-09-01 Epub Date: 2026-06-10 DOI: 10.1080/17476348.2026.2684077

Sergey N Avdeev, Galina L Ignatova, Oxana M Drapkina, Veronica B Popova, Ekaterina V Melnikova, Tatiana I Chudinovskikh, Olga V Ryabova, Natalia V Egorova, Tamara V Rubanik, Yury G Shvarts, Svetlana A Polyakova, Anna V Antonova, Dmitry A Zubkov, Mikhail S Khmelevskii, Nadezhda F Khomyakova, Mikhail A Tsyferov, Tim C Hardman, Anton A Tikhonov

{"title":"Bovhyaluronidase azoximer for long-term pulmonary sequelae of COVID19: a multicenter, randomized, double-blind, placebo-controlled study.","authors":"Sergey N Avdeev, Galina L Ignatova, Oxana M Drapkina, Veronica B Popova, Ekaterina V Melnikova, Tatiana I Chudinovskikh, Olga V Ryabova, Natalia V Egorova, Tamara V Rubanik, Yury G Shvarts, Svetlana A Polyakova, Anna V Antonova, Dmitry A Zubkov, Mikhail S Khmelevskii, Nadezhda F Khomyakova, Mikhail A Tsyferov, Tim C Hardman, Anton A Tikhonov","doi":"10.1080/17476348.2026.2684077","DOIUrl":"10.1080/17476348.2026.2684077","url":null,"abstract":"Background: Bovhyaluronidase azoximer (BA) has been reported to improve pulmonary function and exercise tolerance in patients with pulmonary sequelae of COVID-19. In this multicenter, randomized, double-blind, placebo-controlled study, we evaluated the effects of BA on patients with long-term (up to 12 months) pulmonary sequelae of COVID-19.Methods: Patients (n = 392) were randomized 1:1 to receive BA or placebo every 5 days for 71 days. Percent predicted forced vital capacity (ppFVC), respiratory symptoms, and exercise tolerance indicators were assessed at baseline and on Days 71 (Δ ppFVC was the primary endpoint) and 180.Results: The pre-specified primary endpoint (Δ ppFVC at Day 71) was negative (+0.30%, p = 0.817). Secondary endpoints showed reduced exertional desaturation (OR 0.36, p = 0.006) and dyspnea (OR 0.62, p = 0.040).Conclusion: While the primary objective yielded clinically insignificant results, patients treated with BA showed increased exercise tolerance although further investigations are required to confirm findings.Trial registration: The study is registered at ClinicalTrials.gov (NCT06383819).","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1137-1147"},"PeriodicalIF":2.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148207387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Delivery of care for pediatric laryngotracheal stenosis. 小儿喉气管狭窄的护理交付。

IF 2.7

Expert review of respiratory medicine Pub Date : 2026-09-01 Epub Date: 2026-06-03 DOI: 10.1080/17476348.2026.2676349

Anisha R Noble, Matthew M Smith

{"title":"Delivery of care for pediatric laryngotracheal stenosis.","authors":"Anisha R Noble, Matthew M Smith","doi":"10.1080/17476348.2026.2676349","DOIUrl":"10.1080/17476348.2026.2676349","url":null,"abstract":"Introduction: Management of pediatric laryngotracheal stenosis remains a complex and multidisciplinary process, with implications of surgery that extend far beyond the operating room. Ideal care for pediatric patients undergoing complex airway reconstruction requires a holistic approach that includes attention to patient and caregiver needs, quality of life measures, and the optimization of secondary outcomes of surgery, such as voicing and swallowing.Areas covered: This special report highlights the impact of non-surgical and secondary outcomes of complex airway reconstruction in pediatric patients with laryngotracheal stenosis. Articles queried from PubMed are reviewed in this report, with special attention to literature that focuses on quality-of-life metrics after pediatric airway reconstruction and that which examines post-operative dysphonia and dysphagia in this population. Additional insight and data from a high-volume pediatric airway reconstructive center are included in this discussion.Expert opinion: Comprehensive care of a pediatric patient with laryngotracheal stenosis extends beyond surgery and involves multidisciplinary management of long-term sequelae to truly improve the quality of life of patients and their caregivers.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1039-1043"},"PeriodicalIF":2.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148058952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact and management of biologic therapies on small airway dysfunction in severe asthma: a comprehensive review. 生物治疗对严重哮喘小气道功能障碍的影响和管理：一项全面的综述。

IF 2.7

Expert review of respiratory medicine Pub Date : 2026-08-30 DOI: 10.1080/17476348.2026.2727155

Francesco Menzella, Rory Chan, Marcello Cottini, Claudio Micheletto

{"title":"Impact and management of biologic therapies on small airway dysfunction in severe asthma: a comprehensive review.","authors":"Francesco Menzella, Rory Chan, Marcello Cottini, Claudio Micheletto","doi":"10.1080/17476348.2026.2727155","DOIUrl":"https://doi.org/10.1080/17476348.2026.2727155","url":null,"abstract":"Introduction: Despite significant advances in precision medicine, managing severe asthma remains a major clinical challenge. Small airway dysfunction (SAD) is a crucial determinant of poor symptom control, airway remodeling, and frequent exacerbations. While conventional spirometry primarily assesses large airway mechanics, airway oscillometry (AO) provides a highly sensitive, effort-independent evaluation of peripheral resistance and reactance during normal breathing.Areas covered: This review synthesizes current evidence from major biomedical databases (PubMed, Embase, Scopus, and Web of Science; 2000-2026) regarding the physiological role of SAD across severe asthma phenotypes (eosinophilic vs. non-eosinophilic). Furthermore, it systematically evaluates the specific impact of targeted biological therapies (anti-IgE, anti-IL-5/IL-5 R, anti-IL-4/13 Rα, and anti-TSLP) on distal respiratory mechanics.Expert opinion: SAD represents a vital treatable trait in severe asthma. Biologics exert distinct physiological effects on peripheral parameters, with upstream modulators such as dupilumab and tezepelumab demonstrating superior efficacy in reversing distal mucus plugging and frequency-dependent resistance abnormalities. Incorporating AO into routine clinical algorithms alongside T2 inflammatory biomarkers is essential to refine endophenotyping, improve overall risk stratification, guide personalized biologic selection, and accurately monitor functional therapeutic responses in patients with severe refractory asthma.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1-12"},"PeriodicalIF":2.7,"publicationDate":"2026-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148868610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effect of the respiratory rate on mechanical power and patient outcomes - a systematic review. 呼吸频率对机械动力和患者预后的影响——一项系统综述。

IF 2.7

Expert review of respiratory medicine Pub Date : 2026-08-28 DOI: 10.1080/17476348.2026.2724585

Jan Willem H J Geerts, Bibi Bosman, M H G Papenhuijzen, Juliana Ferreira, David van Meenen, Frederique Paulus, Marcus J Schultz, Kanwalpreet Sodhi, Louise Urlings-Strop, Laura A Buiteman-Kruizinga

{"title":"The effect of the respiratory rate on mechanical power and patient outcomes - a systematic review.","authors":"Jan Willem H J Geerts, Bibi Bosman, M H G Papenhuijzen, Juliana Ferreira, David van Meenen, Frederique Paulus, Marcus J Schultz, Kanwalpreet Sodhi, Louise Urlings-Strop, Laura A Buiteman-Kruizinga","doi":"10.1080/17476348.2026.2724585","DOIUrl":"10.1080/17476348.2026.2724585","url":null,"abstract":"Introduction: Mechanical power (MP) is associated with worse clinical outcomes. Respiratory rate (RR) is a key component of MP. The aim of this systematic review was to assess whether, among mechanically ventilated adult ICU patients, a low versus high RR is associated with differences in MP, clinical outcomes and ventilation parameters.Methods: A comprehensive systematic search in PubMed, Embase, Cochrane Central Register of Controlled Trials and Google Scholar was performed in January 2026. Studies were included if they reported on invasively ventilated adult patients in the ICU and evaluated RR in relation to MP or patient outcomes.Results: 12 studies were included. Most studies involved patients with ARDS or COVID-19. Lower RR was associated with reduced MP across most studies. Studies using automated ventilation or protocolized RR adjustments showed the largest reductions in MP. Higher RR was associated with increased mortality in three studies. Reducing RR did not lead to significant changes in other ventilation parameters or gas exchange.Conclusion: Lowering RR is a promising strategy to reduce MP with minimal effects on gas exchange over short durations. RR may represent an underrecognized setting in lung-protective ventilation, but prospective studies are needed to confirm effects on clinical outcomes.Study registration: The search strategy was registered at PROSPERO (registration number CRD420251240779).","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1-11"},"PeriodicalIF":2.7,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148835785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Early-life respiratory infections and their association with chronic lung disease: an expert perspective. 生命早期呼吸道感染及其与慢性肺病的关系：专家观点

IF 2.7

Expert review of respiratory medicine Pub Date : 2026-08-27 DOI: 10.1080/17476348.2026.2725279

Susanna Esposito, Valentina Fainardi, Nicola Principi

{"title":"Early-life respiratory infections and their association with chronic lung disease: an expert perspective.","authors":"Susanna Esposito, Valentina Fainardi, Nicola Principi","doi":"10.1080/17476348.2026.2725279","DOIUrl":"10.1080/17476348.2026.2725279","url":null,"abstract":"Introduction: Early-life respiratory infections may disrupt lung development during critical fetal, neonatal, and infant windows, when alveolarization, airway and vascular maturation, and immune programming remain active, potentially causing effects beyond the acute illness.Areas covered: This narrative review examines prenatal and postnatal respiratory infections and long-term respiratory outcomes, with emphasis on chorioamnionitis, fetal inflammatory responses, bronchopulmonary dysplasia, respiratory syncytial virus, and other pathogens. Literature was identified through targeted searches of biomedical databases and reference lists using terms related to early-life infection, lung development, bronchopulmonary dysplasia, wheeze, asthma, lung function, COPD, and respiratory mortality. Priority was given to systematic reviews, meta-analyses, longitudinal cohorts, mechanistic studies, and relevant reports. Proposed pathways include impaired alveolar and vascular growth, epithelial injury, immune dysregulation, trained immunity, airway remodeling, and reduced peak lung function. Epidemiological evidence linking early lower respiratory tract infection with recurrent wheeze, asthma, impaired lung function, COPD-like trajectories, and respiratory mortality is appraised.Expert opinion: Early respiratory infections likely contribute to chronic morbidity through interactions among pathogen, timing, host susceptibility, prematurity, and environmental exposures. Causality remains difficult to establish. Newly available respiratory syncytial virus prevention strategies may clarify whether preventing severe infection improves long-term lung health. Standardized outcomes and longitudinal follow-up are essential.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1-13"},"PeriodicalIF":2.7,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148820698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sepsis risk in patients with COPD and type 2 diabetes mellitus: influence of emerging antihyperglycemic therapies. COPD合并2型糖尿病患者脓毒症风险：新出现的降糖疗法的影响

IF 2.7

Expert review of respiratory medicine Pub Date : 2026-08-13 DOI: 10.1080/17476348.2026.2713233

Kuan-Chih Kuo, Chao-Hsien Chen, Ting-Jia Wu, Hsiu-Chin Wu, Ya-Hui Wang, Cheng-Yi Wang, Chih-Cheng Lai, Vin-Cent Wu

{"title":"Sepsis risk in patients with COPD and type 2 diabetes mellitus: influence of emerging antihyperglycemic therapies.","authors":"Kuan-Chih Kuo, Chao-Hsien Chen, Ting-Jia Wu, Hsiu-Chin Wu, Ya-Hui Wang, Cheng-Yi Wang, Chih-Cheng Lai, Vin-Cent Wu","doi":"10.1080/17476348.2026.2713233","DOIUrl":"10.1080/17476348.2026.2713233","url":null,"abstract":"Background and objective: Patients with chronic obstructive pulmonary disease (COPD) and type 2 diabetes mellitus (T2DM) are at increased risk of sepsis, yet the comparative infection-related outcomes of newer antihyperglycemic agents remain unclear. We evaluated the associations of glucagon-like peptide-1 receptor agonists (GLP-1RAs) versus sodium-glucose cotransporter-2 inhibitors (SGLT2is) with infection outcomes in this population.Methods: In this retrospective cohort study using the TriNetX global federated database, individuals aged 40-100 years with coexisting COPD and T2DM who initiated a GLP-1RA or SGLT2i between 2021 and 2024 were identified. A new-user, active-comparator design with 1:1 propensity score matching was applied. Sepsis was the primary outcome; all-cause mortality and components of the primary outcome were secondary. Cox proportional hazards models estimated hazard ratios (HRs) with 95% confidence intervals (CIs).Results: After matching, 45,491 pairs were included. Compared with SGLT2is, GLP-1RAs showed lower risks of sepsis (adjusted HR, 0.832; 95% CI, 0.781-0.887), all-cause mortality (0.642; 0.598-0.689), and severe sepsis (0.841; 0.774-0.914).Conclusion: In patients with COPD and T2DM, GLP-1RAs were associated with significantly lower risks of sepsis and all-cause mortality compared with SGLT2is.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1-11"},"PeriodicalIF":2.7,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148664865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Accurate health information is the best strategy against misinformation and disinformation: respiratory specialists are on the front line. 准确的健康信息是对抗错误信息和虚假信息的最佳策略：呼吸系统专家站在第一线。

IF 2.7

Expert review of respiratory medicine Pub Date : 2026-08-10 DOI: 10.1080/17476348.2026.2716433

Mathieu Molimard, Dominique Costagliola, Hervé Maisonneuve

{"title":"Accurate health information is the best strategy against misinformation and disinformation: respiratory specialists are on the front line.","authors":"Mathieu Molimard, Dominique Costagliola, Hervé Maisonneuve","doi":"10.1080/17476348.2026.2716433","DOIUrl":"10.1080/17476348.2026.2716433","url":null,"abstract":"Introduction: Disinformation refers to false information deliberately shared with the intent to cause harm. Disinformation is escalating because health is a global concern and tends to elicit strong emotional responses. Misinformation refers to false information shared without malicious intent.Areas covered: Health-related misinformation and disinformation undermine prevention efforts, distort health behaviors, and erode trust in institutions and professionals. A French mission identified three vulnerabilities: low health literacy, difficulty in assessing the reliability of sources, and algorithm-driven exposure to information. Current responses remain fragmented, scientists are frequently targeted, and those spreading disinformation are rarely sanctioned. The strategy we propose rests on six pillars (education, training, improved information systems, detection, sanctions, and strengthened research) coupled with coordinated action at national and European levels. Respiratory health stands at the crossroads of several highly contested domains: tobacco and nicotine products, air pollution, chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease, and respiratory infections, including COVID-19, influenza, and respiratory syncytial virus infections.Expert opinion: Respiratory societies have called for defending independent science, countering online disinformation, and strengthening international collaboration. Learned societies, regulators and EU institutions must align their efforts across research, policy, and the oversight of social media platforms.","PeriodicalId":94007,"journal":{"name":"Expert review of respiratory medicine","volume":" ","pages":"1-6"},"PeriodicalIF":2.7,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148687115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Microscopy versus confocal laser endomicroscopy for EBUS-TBNA: pros and cons. 显微镜与共聚焦激光内镜检查EBUS-TBNA：利弊。

IF 2.7

Expert review of respiratory medicine Pub Date : 2026-08-03 DOI: 10.1080/17476348.2026.2713234

Paul Zarogoulidis

引用次数: 0